These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 6253098)

  • 21. Dose-response curves for predicting misonidazole-induced peripheral neuropathy.
    Schwade JG; Makuch RW; Strong JM; Glatstein E
    Cancer Treat Rep; 1982 Sep; 66(9):1743-50. PubMed ID: 6288238
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The use of misonidazole in association with a three-fractions per day regimen in advanced head and neck epidermoid cancer. A pilot study.
    Awwad HK; Barsoum M; El Merzabani M; Omar S; El Badawy S; Ezzat S; El Baki HA; Zaki A
    Am J Clin Oncol; 1983 Feb; 6(1):91-7. PubMed ID: 6301258
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Cambridge glioma trial of misonidazole and radiation therapy with associated pharmacokinetic studies.
    Bleehen NM
    Cancer Clin Trials; 1980; 3(3):267-73. PubMed ID: 7002338
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Skin rashes associated with the administration of the 2-nitroimidazole, misonidazole.
    Saunders MI; Dische S; Kogelnik HD; Sealy R; Lenox-Smith I
    Cancer Treat Rep; 1980; 64(2-3):263-8. PubMed ID: 6447539
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical trials of misonidazole in the United States.
    Wasserman TH; Stetz J; Phillips TL
    Cancer Clin Trials; 1981; 4(1):7-16. PubMed ID: 7214664
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationship between the neurotoxicity of the hypoxic cell radiosensitizer SR 2508 and the pharmacokinetic profile.
    Coleman CN; Halsey J; Cox RS; Hirst VK; Blaschke T; Howes AE; Wasserman TH; Urtasun RC; Pajak T; Hancock S
    Cancer Res; 1987 Jan; 47(1):319-22. PubMed ID: 3024818
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery; preliminary results of an RTOG study.
    Nelson DF; Schoenfeld D; Weinstein AS; Nelson JS; Wasserman T; Goodman RL; Carabell S
    Int J Radiat Oncol Biol Phys; 1983 Aug; 9(8):1143-51. PubMed ID: 6347995
    [TBL] [Abstract][Full Text] [Related]  

  • 28. I.V. misonidazole (NSC 261037). Report of initial clinical experience.
    Schwade JG; Strong JM; Gangji D
    Cancer Clin Trials; 1981; 4(1):33-9. PubMed ID: 7214660
    [No Abstract]   [Full Text] [Related]  

  • 29. A study of the effect of misonidazole in conjunction with radiotherapy for the treatment of head and neck cancer. MRC working party on misonidazole in head and neck cancer.
    Br J Radiol; 1984 Jul; 57(679):585-95. PubMed ID: 6329395
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preliminary results of RTOG phase I/II study of misonidazole and radiation for bladder cancer.
    Mohiuddin M; Kramer S; Phillips T; Soberon M; Forgione H
    Am J Clin Oncol; 1982 Oct; 5(5):551-4. PubMed ID: 7180834
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of microsomal enzyme inducers in the reduction of misonidazole neurotoxicity.
    Jones DH; Bleehen NM; Workman P; Smith NC
    Br J Radiol; 1983 Nov; 56(671):865-70. PubMed ID: 6626878
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Misonidazole cytotoxicity in vivo: a comparison of large single doses with smaller doses and extended contact of the drug with tumor cells.
    Conroy PJ; Sutherland RM; Passalacqua W
    Radiat Res; 1980 Jul; 83(1):169-89. PubMed ID: 7394163
    [No Abstract]   [Full Text] [Related]  

  • 33. Misonidazole neuropathy.
    Paulson OB; Melgaard B; Hansen HS; Kamieniecka Z; Køhler O; Hansen JM; Pedersen AG; Tang X; Trojaborg W
    Acta Neurol Scand Suppl; 1984; 100():133-6. PubMed ID: 6091392
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multiple daily fractionation (MDF) radiotherapy in association with hyperthermia and/or misonidazole: experimental and clinical results.
    Arcangeli G; Barocas A; Mauro F; Nervi C; Spanò M; Tabocchini A
    Cancer; 1980 Jun; 45(11):2707-11. PubMed ID: 7379004
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The clinical phase I study of TNP-351. The TNP-351 Research Committee].
    Taguchi T; Niitani H; Furue H; Tsukagoshi S; Kanamaru R; Hasegawa K; Akazawa S; Yoneda S; Tominaga T; Sasaki T
    Gan To Kagaku Ryoho; 1995 Feb; 22(2):259-71. PubMed ID: 7857102
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low-dose valproate: a new treatment for cyclothymia, mild rapid cycling disorders, and premenstrual syndrome.
    Jacobsen FM
    J Clin Psychiatry; 1993 Jun; 54(6):229-34. PubMed ID: 8331092
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radiation Therapy Oncology Group clinical trials with misonidazole.
    Wasserman TH; Stetz J; Phillips TL
    Cancer; 1981 May; 47(10):2382-90. PubMed ID: 7023642
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG).
    Toma S; Tucci A; Villani G; Carteni G; Spadini N; Palumbo R
    Anticancer Res; 2000; 20(1B):485-91. PubMed ID: 10769710
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical testing of the radiosensitizer RO-07-0582 (misonidazole). Dose tolerance, toxicity and pharmacokinetic studies, preliminary report (author's transl)].
    Bataini JP; Bernier J; de Narbonne J; Brugère J; Jaulerry C; Brunin F
    Bull Cancer; 1978; 65(4):482-5. PubMed ID: 371710
    [No Abstract]   [Full Text] [Related]  

  • 40. Misonidazole dose and tumor level relationships. Effects of individual variation in rate of misonidazole metabolism and absorption from the gastrointestinal tract.
    Strong JM; Schwade JG; Gangji D; Shoemaker DD; Upton DK
    Cancer Clin Trials; 1981; 4(1):41-6. PubMed ID: 7214661
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.